Inhibition of the brain deposition of hIAPP by GLP-1 agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors can reduce the development of AD in T2D (Alrouji et al. 2023). This evidence concerns the gene DPP4 and Alzheimer disease.